WEBSITE BSE:543427 NSE : MEDPLUS 10 May, 16:01
Market Cap ₹8384 Cr.
Stock P/E 142.7
P/B 5.4
Current Price ₹701.4
Book Value ₹ 128.9
Face Value 2
52W High ₹977.5
Dividend Yield 0%
52W Low ₹ 598
MedPlus Health Services Ltd engages in the retail buying and selling of medicines and general items in India. It offers pharmaceutical and wellbeing products, including medicines, vitamins, medical gadgets, and test kits; fast-shifting customer goods, such as toiletries, infant care products, soaps, detergents, and sanitizers. The organisation additionally offers wholesale cash and carry, and pathological laboratory testing offerings, in addition to engages within the settlement manufacturing of private label prescribed drugs. As of March 31, 2021, it operated thru 1,659 shops in the states of Karnataka, Tamil Nadu, Telangana, and Andhra Pradesh, as well as via its online shop. The enterprise was founded in 2006 and is based in Hyderabad, India.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
#(Fig in Cr.) | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 925 | 933 | 966 | 994 | 1121 | 1190 | 1253 | 1284 | 1409 | 1441 |
Other Income | 7 | 7 | 13 | 10 | 11 | 11 | 14 | 9 | 10 | 10 |
Total Income | 932 | 941 | 979 | 1004 | 1132 | 1202 | 1267 | 1294 | 1419 | 1451 |
Total Expenditure | 863 | 872 | 914 | 941 | 1061 | 1119 | 1171 | 1213 | 1323 | 1350 |
Operating Profit | 69 | 69 | 65 | 63 | 71 | 83 | 95 | 81 | 95 | 102 |
Interest | 16 | 17 | 19 | 20 | 20 | 21 | 22 | 23 | 24 | 24 |
Depreciation | 28 | 30 | 34 | 38 | 42 | 46 | 56 | 52 | 55 | 57 |
Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit Before Tax | 25 | 22 | 13 | 5 | 9 | 16 | 17 | 5 | 16 | 20 |
Provision for Tax | 5 | 5 | 1 | 1 | 2 | 3 | -9 | 1 | 2 | 6 |
Profit After Tax | 20 | 17 | 11 | 4 | 6 | 13 | 27 | 4 | 15 | 14 |
Adjustments | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit After Adjustments | 20 | 17 | 12 | 3 | 7 | 13 | 27 | 4 | 15 | 14 |
Adjusted Earnings Per Share | 6.3 | 1.4 | 1 | 0.3 | 0.6 | 1.1 | 2.2 | 0.3 | 1.2 | 1.1 |
#(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 1368 | 1733 | 2011 | 2132 | 2273 | 2871 | 3069 | 3779 | 4558 | 5387 |
Other Income | 4 | 9 | 8 | 7 | 10 | 17 | 22 | 31 | 46 | 43 |
Total Income | 1373 | 1742 | 2020 | 2139 | 2283 | 2888 | 3091 | 3811 | 4604 | 5431 |
Total Expenditure | 1333 | 1691 | 1935 | 2073 | 2216 | 2737 | 2840 | 3490 | 4276 | 5057 |
Operating Profit | 40 | 50 | 85 | 66 | 67 | 151 | 251 | 320 | 327 | 373 |
Interest | 17 | 22 | 25 | 28 | 16 | 47 | 67 | 83 | 99 | 93 |
Depreciation | 9 | 10 | 11 | 12 | 14 | 75 | 88 | 119 | 182 | 220 |
Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit Before Tax | 14 | 19 | 48 | 26 | 37 | 29 | 95 | 118 | 47 | 58 |
Provision for Tax | 6 | 10 | 19 | -17 | 16 | 28 | 32 | 23 | -3 | 0 |
Profit After Tax | 7 | 9 | 29 | 42 | 21 | 2 | 63 | 95 | 50 | 60 |
Adjustments | 0 | -0 | -0 | 0 | 0 | 0 | 1 | 1 | -0 | 0 |
Profit After Adjustments | 7 | 9 | 29 | 42 | 21 | 2 | 64 | 96 | 50 | 60 |
Adjusted Earnings Per Share | 39.4 | 47.8 | 152.3 | 194.1 | 95.8 | 8.2 | 285.1 | 8 | 4.2 | 4.8 |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Sales CAGR | 21% | 17% | 16% | 0% |
Operating Profit CAGR | 2% | 29% | 38% | 0% |
PAT CAGR | -47% | 192% | 4% | 0% |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Share Price CAGR | -7% | NA% | NA% | NA% |
ROE Average | 4% | 8% | 6% | 9% |
ROCE Average | 10% | 16% | 15% | 14% |
#(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|---|---|---|---|---|
Shareholder's Funds | 154 | 149 | 160 | 303 | 325 | 528 | 731 | 1418 | 1491 |
Minority's Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | -1 | -1 |
Borrowings | 62 | 65 | 54 | 8 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 18 | 34 | -27 | 10 | 327 | 399 | 647 | 797 |
Total Current Liabilities | 210 | 269 | 276 | 325 | 337 | 498 | 445 | 559 | 477 |
Total Liabilities | 430 | 501 | 525 | 610 | 672 | 1354 | 1575 | 2624 | 2764 |
Fixed Assets | 67 | 77 | 81 | 83 | 90 | 419 | 517 | 799 | 1138 |
Other Non-Current Assets | 46 | 48 | 49 | 69 | 107 | 102 | 105 | 193 | 146 |
Total Current Assets | 317 | 376 | 395 | 458 | 475 | 833 | 953 | 1632 | 1481 |
Total Assets | 430 | 501 | 525 | 610 | 672 | 1354 | 1575 | 2624 | 2764 |
#(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|---|---|---|---|---|
Opening Cash & Cash Equivalents | 13 | 46 | 31 | 21 | 35 | -47 | 9 | -28 | -121 |
Cash Flow from Operating Activities | -19 | -17 | 34 | 32 | 82 | -7 | 3 | 170 | 90 |
Cash Flow from Investing Activities | -15 | -32 | -15 | -18 | -20 | -28 | -35 | -703 | 429 |
Cash Flow from Financing Activities | 66 | 35 | -29 | -1 | -72 | 90 | -6 | 440 | -170 |
Net Cash Inflow / Outflow | 32 | -15 | -10 | 14 | -10 | 56 | -37 | -93 | 350 |
Closing Cash & Cash Equivalent | 45 | 31 | 21 | 35 | 24 | 9 | -28 | -121 | 228 |
# | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|---|---|---|---|---|
Earnings Per Share (Rs) | 39.43 | 47.84 | 152.33 | 194.06 | 95.77 | 8.22 | 285.08 | 8.03 | 4.17 |
CEPS(Rs) | 85.43 | 100.33 | 212.89 | 251.21 | 159.72 | 350.98 | 675.81 | 17.94 | 19.42 |
DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Book NAV/Share(Rs) | 716.21 | 694.75 | 752.08 | 1363.1 | 1450.49 | 2378.5 | 3044.19 | 117.89 | 122.44 |
Core EBITDA Margin(%) | 2.61 | 2.39 | 3.81 | 2.75 | 2.5 | 4.65 | 7.32 | 7.54 | 6.08 |
EBIT Margin(%) | 2.28 | 2.33 | 3.65 | 2.5 | 2.32 | 2.65 | 5.19 | 5.24 | 3.15 |
Pre Tax Margin(%) | 1.01 | 1.08 | 2.38 | 1.2 | 1.61 | 1.02 | 3.04 | 3.08 | 1.02 |
PAT Margin (%) | 0.55 | 0.52 | 1.43 | 1.99 | 0.92 | 0.06 | 2.01 | 2.47 | 1.08 |
Cash Profit Margin (%) | 1.18 | 1.1 | 2 | 2.57 | 1.53 | 2.67 | 4.83 | 5.59 | 5.01 |
ROA(%) | 1.73 | 1.94 | 5.62 | 7.47 | 3.26 | 0.18 | 4.31 | 4.51 | 1.86 |
ROE(%) | 5.51 | 6.78 | 21.06 | 19.26 | 6.81 | 0.43 | 10.51 | 9.07 | 3.5 |
ROCE(%) | 10.02 | 12.04 | 20.61 | 13.06 | 11.77 | 14.34 | 21.69 | 16.56 | 9.56 |
Receivable days | 1.03 | 0.77 | 0.53 | 1.09 | 1.53 | 0.96 | 0.69 | 0.54 | 0.58 |
Inventory Days | 67.6 | 59.37 | 58.51 | 59.74 | 60.81 | 65.93 | 81.18 | 79.28 | 81.27 |
Payable days | 34.09 | 28.02 | 24.9 | 25.21 | 28.85 | 31 | 28.76 | 24.13 | 25.98 |
PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 125.8 | 156.11 |
Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.57 | 5.32 |
Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EV/Net Sales(x) | 0.09 | 0.1 | 0.08 | 0.05 | 0.02 | -0.01 | 0.01 | 3.22 | 1.64 |
EV/Core EBITDA(x) | 3.07 | 3.44 | 1.92 | 1.59 | 0.82 | -0.23 | 0.07 | 37.97 | 22.86 |
Net Sales Growth(%) | 0 | 26.64 | 16.07 | 5.99 | 6.61 | 26.31 | 6.92 | 23.13 | 20.59 |
EBIT Growth(%) | 0 | 29.35 | 81.5 | -27.21 | -1.32 | 44.56 | 113.38 | 23.63 | -27.38 |
PAT Growth(%) | 0 | 21.32 | 218.43 | 46.9 | -50.65 | -91.42 | 3417.89 | 50.08 | -47.1 |
EPS Growth(%) | 0 | 21.31 | 218.43 | 27.39 | -50.65 | -91.42 | 3368.17 | -97.18 | -48.06 |
Debt/Equity(x) | 1.07 | 1.46 | 1.24 | 0.55 | 0.33 | 0.2 | 0.2 | 0.1 | 0 |
Current Ratio(x) | 1.51 | 1.4 | 1.43 | 1.41 | 1.41 | 1.67 | 2.14 | 2.92 | 3.11 |
Quick Ratio(x) | 0.3 | 0.25 | 0.22 | 0.29 | 0.24 | 0.38 | 0.46 | 1.28 | 0.71 |
Interest Cover(x) | 1.79 | 1.86 | 2.89 | 1.92 | 3.27 | 1.63 | 2.41 | 2.42 | 1.48 |
Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0 |
# | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Promoter | 40.43 | 40.43 | 40.43 | 40.43 | 40.43 | 40.43 | 40.43 | 40.41 | 40.45 | 40.39 |
FII | 3.42 | 2.97 | 3.15 | 3.74 | 3.95 | 4.49 | 4.86 | 12.36 | 12.97 | 14.94 |
DII | 27.72 | 29.24 | 29.48 | 28.84 | 28.77 | 28.16 | 28.14 | 25.49 | 25.18 | 22.47 |
Public | 28.43 | 27.36 | 26.94 | 26.99 | 26.85 | 26.93 | 26.57 | 21.74 | 21.4 | 22.2 |
Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
# | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Promoter | 4.82 | 4.82 | 4.82 | 4.82 | 4.82 | 4.82 | 4.82 | 4.82 | 4.83 | 4.83 |
FII | 0.41 | 0.35 | 0.38 | 0.45 | 0.47 | 0.54 | 0.58 | 1.48 | 1.55 | 1.79 |
DII | 3.31 | 3.49 | 3.52 | 3.44 | 3.43 | 3.36 | 3.36 | 3.04 | 3.01 | 2.69 |
Public | 3.39 | 3.26 | 3.21 | 3.22 | 3.2 | 3.21 | 3.17 | 2.59 | 2.55 | 2.65 |
Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 11.93 | 11.93 | 11.93 | 11.93 | 11.93 | 11.93 | 11.93 | 11.94 | 11.94 | 11.95 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
You May Also Know About